Multiple Myeloma Treatment Algorithm
Transplant-Eligible Patients
For newly diagnosed transplant-eligible patients, quadruplet induction therapy with daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRd) should be offered, followed by autologous stem cell transplantation (ASCT) and lenalidomide maintenance with or without daratumumab. 1
Induction Therapy (3-6 cycles before ASCT)
Standard-risk disease:
- VRd (bortezomib-lenalidomide-dexamethasone) remains acceptable as triplet therapy 2, 3
- Quadruplet therapy with Dara-VRd or isatuximab-VRd is increasingly preferred for deeper responses 1, 4
High-risk disease (del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation):
- Dara-VRd is strongly recommended over triplet therapy 2, 3
- Double-hit (≥2 high-risk factors) or triple-hit (≥3 high-risk factors) myeloma requires quadruplet induction 2
Stem Cell Collection and Transplantation
- Perform stem cell collection after 4-6 cycles of induction 3, 5
- Selected standard-risk patients may delay ASCT until first relapse after collecting stem cells 2, 3
- High-dose melphalan conditioning followed by ASCT remains standard 4, 5
Maintenance Therapy Post-ASCT
Standard-risk patients:
High-risk patients:
- Bortezomib plus lenalidomide combination maintenance 2, 3
- Consider adding daratumumab, carfilzomib, and/or dexamethasone 1
Transplant-Ineligible Patients
For transplant-ineligible patients, quadruplet therapy with daratumumab or isatuximab combined with bortezomib, lenalidomide, and dexamethasone should be offered as initial therapy. 1
Induction and Continuous Therapy
Standard-risk disease:
- DRd (daratumumab-lenalidomide-dexamethasone) continued until progression is preferred 3
- VRd for 8-12 cycles followed by maintenance is an alternative 2
High-risk disease:
- Bortezomib-containing regimens: VRd or VRd-lite 3
- Consider quadruplet therapy with daratumumab or isatuximab 1
Relapsed/Refractory Multiple Myeloma
Patients with relapsed or refractory disease should receive triplet therapy or T-cell redirecting therapies based on prior treatment exposure and disease characteristics. 1
After 1-3 Prior Therapies
Category 1 options (NCCN):
- Bortezomib/liposomal doxorubicin/dexamethasone (extends median time to progression from 6.5 to 9.3 months) 6
Other recommended regimens:
- Elotuzumab/bortezomib/dexamethasone (median PFS 9.7 vs 6.9 months; 24% relative risk reduction) 6
- Lenalidomide/cyclophosphamide/dexamethasone (effective in heavily pretreated patients) 6
- Ixazomib/cyclophosphamide/dexamethasone (all-oral regimen; median PFS 14.2 months, better in patients ≥65 years) 6
After ≥2 Prior Therapies (Including IMiD and PI)
For patients with progression on/within 60 days of last therapy:
- Pomalidomide/cyclophosphamide/dexamethasone (63% response rate, 80.7% one-year PFS) 6
- Daratumumab/bortezomib/cyclophosphamide/dexamethasone (71.4% ORR after 4 cycles, 57.1% VGPR or better) 6
Key Principles for Relapsed Disease
- Triplet regimens are usually required at each successive relapse 2
- Choice varies with each relapse based on prior exposures and toxicities 2
- T-cell redirecting therapies represent emerging options 1
Critical Caveats
High-risk cytogenetics require intensified therapy at all stages: Standard triplet therapy is insufficient for high-risk disease; quadruplet induction and combination maintenance are essential to improve suboptimal outcomes 2, 3, 5.
Avoid single-agent or doublet induction: These regimens have fallen out of favor and should not be used when triplet or quadruplet options are available 4.
Monitor for grade 3-4 toxicities: Thrombocytopenia occurs in 15-52% depending on regimen; neutropenia and anemia are also common 6. Dose adjustments and supportive care are critical for treatment continuation.